The concept of ocular inserts as drug delivery systems: An overview

Article Sidebar

PDF
Published: Aug 25, 2014
DOI: https://doi.org/10.22377/ajp.v2i4.204

Main Article Content

Deivasigamani Karthikeyan
Mithun Bhowmick
Vijay Prakesh Pandey
Jothivel Nandhakumar
Singaravel Sengottuvelu
Sandeep Sonkar
Thangavel Sivakumar

Abstract

Ocular diseases require localized administration of drugs to the tissues around the ocular cavity. The existing ocular drug delivery systems are fairly primitive and inefficient. However, the design of ocular system is undergoing gradual
transition from an empirical to rational basis. In the recent years, there has been explosion of interest in the polymer based delivery devices. Utilization of the principles of controlled release as embodied by ocular inserts offers an attractive
approach to the problem of prolonging pre-corneal drug residence times. In the present update, the authors discuss the basic concept of ocular inserts as drug delivery system and examine the few inserts, which are available in the market or are being developed by pharmaceutical companies for drug delivery.The article discusses soluble ocular drug insert (SODI), Ocusert, Collagen Shields, Ocufit, Minidisc and new ophthalmic delivery system (NODS) with special attention to biological/clinical performances, and potential for future applications and developments.

Downloads

Download data is not yet available.

Article Details

How to Cite
Karthikeyan, D., Bhowmick, M., Pandey, V. P., Nandhakumar, J., Sengottuvelu, S., Sonkar, S., & Sivakumar, T. (2014). The concept of ocular inserts as drug delivery systems: An overview. Asian Journal of Pharmaceutics (AJP), 2(4). https://doi.org/10.22377/ajp.v2i4.204
Issue
Vol. 2 No. 4 (2008): Oct-Dec
Section
Articles

This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.

References

Chien YW. Ocular drug delivery and delivery systems. In: Novel drug

delivery systems. 2nd ed. New York: Marcel Dekker; 1992. p. 269-70.

Saettone MF, Salminen L. Ocular inserts for topical delivery. Adv Drug

Del Rev 1995;16:95-106.

Khar RK, Vyas SP. Targeted and Controlled drug delivery novel carrier

systems. 1st ed. New Delhi; CBS Publishers and Distributors; 2002.

p. 384.

Gurtler F, Gurny R. Patent literature review of ophthalmic inserts. Drug

Dev Ind Pharm 1995;21:1-18.

Saettone MF. Solid polymeric inserts/disks as ocular drug delivery

systems. In: Edman P, editor. Biopharmaceutics of ocular drug delivery.

Boca Raton: CRC Press; 1993. p. 61-79.

Quigley HA, Pollack IP, Harbin TS Jr. Pilocarpine ocuserts: Long term

clinical trials and selected pharmacodynamics. Arch Ophthalmol

;93:771-5.

Bloomfield SE, Miyata T, Dunn MW, Bueser N, Stenzel KH, Rubin AL.

Soluble artificial tear inserts. Arch Ophthalmol 1977;95:247-50.

Bloomfield SE, Miyata T, Dunn MW, Bueser N, Stenzel KH, Rubin AL.

Soluble gentamicin ophthalmic inserts as a drug delivery system. Arch

Ophthalmol 1978;96:885-7.

Khromow GL, Davydov AB, Maychuk YF, Tishina IF. Base for

ophthalmological medicinal preparations and an ophthalmological

medicinal film. US. Patent 3, 935, 303, 1976.

Maichuk YF. Medicated eye films. Moscow: Med Export; 1985. p.

-66.

Maichuk YF. Polymeric ophthalmic inserts with antibiotics, Proceedings

of the Conference of Ophthalmologists of the City of Moscow; 1967.

p. 403-5.

Lloyd R. U.K. Patent 2097680. Smith and Nephew Research, Ltd;

Milani JK, Verbukh I, Pleyer U, Sumner H, Adamu SA, Halabi HP, et al.

Collagen shields impregnated with gentamicin-dexamethasone as

potential drug delivery device. Am J Ophthalmol 1993;116:622-7.

Wentworth JS, Paterson CA, Wells JT, Tilki N, Gray RS, McCartney MD.

Collagen shields exacerbate ulceration of alkali-burned rabbit corneas.

Arch Ophthalmol 1993;111:389-92.

Kaufman HE, Steinemann TL, Lehman E, Thompson HW, Varnell ED,

Jacob-LaBarre JT, et al. Collagen-based drug delivery and artificial tears.

J Ocul Pharmacol 1994;10:17-27.

Darougar S. Ocular insert for the fornix, U.S. Patent 5,147, 1992,647.

Katz IM, Blackman WM. A soluble sustained-release ophthalmic delivery

unit. Am J Ophthalmol 1977;83:728-34.

Lamberts DW, Pavan-Langston D, Chu W. A clinical study of slow-

releasing artificial tears. Ophthalmology 1978;85:794-800.

Bawa R, Dais M, Nandu M, Robinson JR. New extended release ocular

drug delivery system: Design, characterization and performance

testing of minidisc inserts. Proc Int Symp Control Rel Bioact Mater

;15:106a-b.

Bawa R, Nandu M, Downie W, Robinson JR. Recent studies on the

continuing characterization of minidisc inserts for ocular therapy. Proc

Intern Symp Control Rel Bioact Mater 1989;16:213-4.

Bawa R. Ocular inserts. In: Mitra AK, editor. Ophthalmic Drug Delivery

Systems. New York: Marcel Dekker; 1993. p. 223-59.

Richardson MC, Bentley PH. A new ophthalmic delivery system. In:

Mitra AK, editor. Ophthalmic drug delivery systems. New York: Marcel

Dekker; 1993. p. 355-67.

Kelly J, Molyneux PD, Smith SA, Smith S. Relative bioavailability of

pilocarpine from a novel ophthalmic delivery system and conventional

eye drop formulations. Br J Ophthalmol 1989;7:360-2.

Greaves JL, Wilson CG, Birmingham AT, Bentley PH, Richardson MC.

Scintigraphic studies on the cornea 1 residence of a new ophthalmic

delivery system (NODS): Rate of clearance of a soluble marker in

relation to duration of pharmacological action of pilocarpine. Br J Clin

Pharmacol 1992;33:603-7.

Gurtler F, Kaltsatos V, Boisrame B, Gurny R. Long acting soluble

bioadhesive ophthalmic drug insert (BODI) containing gentamicin for

veterinary use: optimization and clinical investigation. J Control Rel

;33:231-6.

Chetoni P, Di Colo G, Gandi M, Morelli M, Saettone MF, Darougar S.

Silicone rubber/hydrogel composite ophthalmic inserts: Preparation

and preliminary in vitro/in vivo evaluation. Eur J Pharma Biopharm

;46:125-32.

Simamora P, Nadkarni SR, Lee YC, Yalkowsky SH. Controlled delivery

of pilocarpine.2. In vivo evaluation of Gelfoam device. Int J Pharm

;170:209-14.

Diestelhorst M, Grunthal S, Suverkrup R. Dry drops: A new preservative-

free drug delivery system. Graefes Arch Clin Exp Ophthalmol

;237:394-8.

Urquhart J. Development of the Ocusert pilocarpine ocular therapeutic

systems: A case history in ophthalmic product development. In:

Robinson JR, editor. Ophthalmic Drug Delivery Systems, American

Pharmaceutical Association, Washington DC: 1980. p. 105-16.

Hornof M, Weyenberg W, Ludwig A, Bernkop-Schnurch A. Mucoadhesive

ocular insert based on thiolated poly(acrylic acid): Development and in

vivo evaluation in humans. J Controlled Release 2003;89:419-28.

Sasaki H, Nagano T, Sakanaka K, Kawakami S, Nishida K, Nakamura J, et

al. One-side-coated insert as a unique ophthalmic drug delivery system.

J Controlled Release 2003;92:241-7.

Korsmeyer RW, Peppas NA. Macromolecular and modeling aspects of

swelling-controlled systems. In: Roseman TJ, Mansdorf SZ, editors.

Controlled Release Delivery Systems. New York: Marcel Dekker; 1983.

p. 77-90.

Darougar; Sohrab, Darougar and Dayshad, Patent literature review

of ocular inserts. United States Patent 6,264,971, Appl. No. 428967,

Filed on November 4, 1999.

Heller J. Controlled release of biologically active compounds from

bioerodible polymers. Biomaterials 1980;1:51-7.

Heller J. Controlled drug release from monolithic systems. In:

Saettone MF, Bucci G, Speiser P, editors. Ophthalmic Drug Delivery,

Biopharmaceutical, Technological and Clinical Aspects, Fidia Research

Sereis. Vol. 11. Padua: Liviana Press; 1987. p. 179-89.

Refojo MF. Polymers in contact lenses: An overview. Curr Eye Res

;4:719-23.

Moddox YF, Bernstein HN. An evoluation of the bionite hydrophilic

contact lens for use in a ocular drug delivery system. Ann Ophthalmol

;4:789.

Prans R, Brettschneider, Krjci L, Kahvodova. Hydrophilic contact lenses

as a new therapeutic approach for the typical use of chloramphenicol

and tetracycline. Opthalmologica 1972;165:62.

Hull DS, Edechauser HF, Hyndink RA. Ocular penetration of prednisolone and the hydrophilic contact lense Arch Ophthalmol 1974;92:413.

Saettone MF, Chetoni P, Torraca MT, Giannaccini B, Naber L, Conte U,

et al. Application of the compression technique to the manufacture of

Pilocarpine inserts. Acta Pharm Technol 1990;36:15-9.

Saettone MF, Torraca MT, Pagano A, Giannaccini B, Rodriguez L, Cini M.

Controlled release of Pilocarpine from coated polymeric ophthalmic

inserts prepared by extrusion. Int J Pharm 1992;86:159.

Attia MA, Kassem MA, Safwat SM. In vivo per formance of 3-H-

dexamethasone ophthalmic film delivery system in the Rabbit eye. Int

J Pharm 1988;47:21.

Lee VH, Yong Li S, Sasaki H, Saettone MF, Chetoni P. Influence of drug

release rate on systemic timolol absorption from polymeric ocular

inserts in the pigmented rabbit. J Ocular Pharmacol 1994;10:421-9.

Grass GM, Cobby J, Makoid MC. Ocular delivery of Pilocarpine from

erodible matrices. J Pharm Sci 1984;73:618-21.

Punch PI, Slatter DH, Costa ND, Edwards ME. Investigation of gelatin as a possible biodegradable matrix for Sustained delivery of gentamicin

to the bovine eye. J Vet Pharmacol Ther 1985;8:335-8.

Salminen L, Urtti A, Kujari H, Juslin M. Prolonged pulse-entry of

pilocarpine with a soluble drug insert. Greafe’s Arch Clin Exp

Ophthalmol 1983;221:96.

Saettone MF, Chetoni P, Torraca MT, Burgalassi S, Giannaccini

B. Evaluation of muco- adhesive properties and in vivo activity

of ophthalmic vehicles based on hyaluronic acid. Int J Pharm

;51:203.

Urtti A, Salminen L, Miinalainen O. Systemic absorption of

ocular pilocarpine is modified by polymer matrices. Int J Pharm

;23:147.

Sendelbeck L, Moore D, Urqhart J. Comparative distribution of

pilocarpine in ocular tissues of the rabbit during administration by

eyedrop or by membrane-controlled delivery systems. Am J Ophthalmol

;80:274-83.

Yamamoto Y, Kaga Y, Yoshikawa T, Moribe A. Ultra violet-hardenable

adhesive. US Patent. 5145884 , 1992.

Milani JK, Verbukh I, Pleyer U, Sumner H, Adamu SA, Halabi HP, et al.

Collagen shields impregnated with gentaminic-dexamethasone as a

potential drug delivery device. Am J Ophthalmol 1993;116:622-7.

Pavan-Langston D, Langston RH, Geary PA. Idoxuridine ocular insert

therapy: Use in treatment of experimental herpes simplex keratitis.

Arch Ophthalmol 1975;93:1349.

Rastogi SK, Vaya N, Mishra B. Ophthamic inserts: An overview. The

Eastern Pharmacist, February 1996. p. 41-4.

Hiratani H, Fujiwara A, Tamiya Y, Mizutani Y, Alvarez-Lorenzo C. Ocular

release of Timolol from molecularly imprinted soft contact lenses.

Biomaterials 2005;26:1293-8.

Stephane M, Isabelle M, Belkacem H, Marie-Jose S, Patrick B, Yves T, et al. Pharmacodynamics of a new ophthalmic mydriatic insert in healthy

volunteers: Potential alternative as drug delivery system Prior to cataract

surgery, basic and clinical. Pharmacol Toxicol 2006;98:547-54.

Natu MV, Sardinha JP, Correia IJ, Gil MH. Controlled release gelatin

hydrogels and lyophilisates with potential application as ocular inserts.

Biomed Mater 2007;2:241-9.

Pijls RT, Lindemann S, Nuijts RM, Daube GW, Koole LH. Pradofloxacin

release from the OphthaCoil: A new device for sustained delivery of

drugs to the eye. J Drug Deliv Sci Technol 2007;17:87-91.